MARKET

IRD

IRD

Opus Genetics
NASDAQ
1.950
-0.040
-2.01%
Closed 18:31 12/30 EST
OPEN
1.990
PREV CLOSE
1.990
HIGH
1.990
LOW
1.935
VOLUME
252.33K
TURNOVER
0
52 WEEK HIGH
2.591
52 WEEK LOW
0.6500
MARKET CAP
134.48M
P/E (TTM)
-1.1059
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IRD last week (1222-1226)?
Weekly Report · 2d ago
Weekly Report: what happened at IRD last week (1215-1219)?
Weekly Report · 12/22 10:05
The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside
Barchart · 12/20 11:00
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug
TipRanks · 12/19 21:37
OPUS GENETICS INC - ON DEC 17, VIATRIS FILES SUPPLEMENTAL NDA WITH FDA FOR PHENTOLAMINE - SEC FILING
Reuters · 12/19 21:20
Opus Genetics Grants Stock Options to New Employee Under Inducement Plan
Reuters · 12/16 21:01
OPUS GENETICS REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 12/16 21:01
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 12/16 15:01
More
About IRD
Opus Genetics, Inc. is a clinical-stage ophthalmic biotechnology company. The Company is engaged in developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. The Company’s pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Its pipeline also includes OPGx-BEST1 investigational gene therapy, designed to address mutations in the BEST1 gene, which is associated with retinal degeneration. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 being investigated to slow the progression of non-proliferative diabetic retinopathy.

Webull offers Opus Genetics Inc stock information, including NASDAQ: IRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRD stock methods without spending real money on the virtual paper trading platform.